Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

W. Qin; F. Dong; Z. Zhang; B. Hu; S. Chen; Z. Zhu; F. Li; X. Wang; Y. Zhang; Y. Wang; K. Zhen; J. Wang; I. Elalamy; C. Li; Z. Zhai; B. Davidson; C. Wang

Статья

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

W. Qin, F. Dong, Z. Zhang, B. Hu, S. Chen, Z. Zhu, F. Li, X. Wang, Y. Zhang, Y. Wang, K. Zhen, J. Wang, I. Elalamy, C. Li, Z. Zhai, B. Davidson, C. Wang,

2021

https://doi.org/10.1016/j.thromres.2020.11.020

Цитирование

Документы

Источник

Версии

1. Version of Record от 2021-04-27

Метаданные

Об авторах

W. Qin
Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Jianghan University, No.168 Hongkong Road, Jiang'an District, Wuhan City, Hubei Province 430000, China
F. Dong
Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, Beijing, China
Z. Zhang
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, China
B. Hu
Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China
S. Chen
National Clinical Research Center for Respiratory Diseases, China
Z. Zhu
Institute of Basic Research, Chinese Academy of Medical Sciences, China
F. Li
Hematology and Thrombosis Center, Tenon University Hospital, INSERM UMRS 938, Sorbonne University, Paris, France
X. Wang
The First I.M. Sechenov Moscow State Medical University, Moscow, Russian Federation
Y. Zhang
Division of Pulmonary and Critical Care Medicine, Providence Health System, Seattle, WA, United States
Y. Wang
Peking Union Medical College, Chinese Academy of Medical Sciences, China
K. Zhen
J. Wang
I. Elalamy
C. Li
Z. Zhai
B. Davidson
C. Wang

Название журнала

Thrombosis Research

Том

Страницы

19-22

Ключевые слова

amoxicillin; aspartate aminotransferase; azithromycin; C reactive protein; cefamandole; ceftazidime; ceftriaxone; corticosteroid; creatinine; D dimer; fibrinogen; globulin; levofloxacin; low molecular weight heparin; methylprednisolone; piperacillin; procalcitonin; sulbactam; anticoagulant agent; low molecular weight heparin; activated partial thromboplastin time; adult; adult respiratory distress syndrome; aged; anticoagulant therapy; anticoagulation; cohort analysis; controlled study; coronavirus disease 2019; disease severity; drug use; epidemic; female; fibrinogen blood level; gastrointestinal hemorrhage; hospital admission; human; human cell; incidence; invasive ventilation; Letter; leukocyte count; lymphocyte count; major clinical study; male; middle aged; mortality; mortality risk; noninvasive ventilation; observational study; oxygen therapy; priority journal; prophylaxis; prothrombin time; Sequential Organ Failure Assessment Score; sex difference; survival; bleeding; blood; China; drug therapy; epidemiology; hospital mortality; hospitalization; mortality; risk factor; time factor; treatment outcome; very elderly; Adult; Aged; Aged, 80 and over; Anticoagulants; China; COVID-19; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Hospital Mortality; Hospitalization; Humans; Male; Middle Aged; Risk Factors; Time Factors; Treatment Outcome

Издатель

Elsevier Ltd

Тип документа

Letter

Тип лицензии Creative Commons

CC BY-NC-ND

Правовой статус документа

Свободная лицензия

Источник

scopus

Поиск по репозиторию

Статья

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

Похожие публикации

Документы

Источник

Версии

Метаданные